The HLA class-II immunopeptidomes of AAV capsids proteins

• Published in: Frontiers in immunology Vol. 13; p. 1067399
• Main Authors: Brito-Sierra, Carlos A, Lannan, Megan B, Siegel, Robert W, Malherbe, Laurent P
• Format: Journal Article
• Language: English
• Published: Switzerland Frontiers Media S.A 20.12.2022
• Subjects: AAV (Adeno-associated virus); Capsid; Capsid Proteins - genetics; CD4; Dependovirus; gene therapy; HLA Antigens - metabolism; Humans; immunogenicity; Immunology; immunopeptidome; Peptides - metabolism; risk assessment; risk assessment; CD4; AAV (Adeno-associated virus); immunopeptidome; gene therapy; HLA; immunogenicity
• ISSN: 1664-3224; 1664-3224
• DOI: 10.3389/fimmu.2022.1067399

Gene therapies are using Adeno-associated viruses (AAVs) as vectors, but immune responses against the capsids pose challenges to their efficiency and safety. Helper T cell recognition of capsid-derived peptides bound to human leukocyte antigen (HLA) class II molecules is an essential step in the AAV-specific adaptive immunity. Using MHC-associated peptide proteomics, we identified the HLA-DR and HLA-DQ immunopeptidomes of the capsid proteins of three different AAV serotypes (AAV2, AAV6, and AAV9) from a panel of healthy donors selected to represent a majority of allele usage. The identified sequences span the capsids of all serotypes, with AAV2 having the highest peptide count. For all the serotypes, multiple promiscuous peptides were identified and displayed by both HLA-DR and -DQ. However, despite high sequence homology, there were few identical peptides among AAV2, AAV6, and AAV9 immunopeptidomes, and none were promiscuous. Results from this work represent a comprehensive immunopeptidomics research of potential CD4+ T cell epitopes and provide the basis for immunosurveillance efforts for safer and more efficient AAV-based gene therapies.